109568
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
胃癌与胃食管结合部肿瘤患者血清肿瘤标志物状态与临床病理特征及疗效的相关性分析与探讨
Authors Xiao Y, Xing Z , Li Z, Jia G, Cheng P, Chen Y, Sun L, Lu C
Received 9 June 2025
Accepted for publication 6 October 2025
Published 11 October 2025 Volume 2025:18 Pages 1149—1157
DOI https://doi.org/10.2147/OTT.S542740
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Yong Teng
Yifan Xiao,1,* Zhenzhu Xing,2,* Zhaobing Li,3 Gang Jia,4 Peng Cheng,4 Yuming Chen,4 Liang Sun,5 Chuangxin Lu4
1Department of Oncology, Henan University People’s Hospital, Zhengzhou, Henan, 450003, People’s Republic of China; 2Department of Oncology, Zhengzhou University People’s Hospital (Henan Provincial People’s Hospital), Zhengzhou, Henan, 450003, People’s Republic of China; 3Department of Medical Records Management, Henan Provincial People’s Hospital, Zhengzhou, Henan, 450003, People’s Republic of China; 4Department of Oncology, Henan Provincial People’s Hospital, Zhengzhou, Henan, 450003, People’s Republic of China; 5School of Public Health, Zhengzhou University, Zhengzhou, Henan, 450001, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Chuangxin Lu, Department of Oncology, Zhengzhou University People’s Hospital (Henan Provincial People’s Hospital), Zhengzhou, Henan, 450003, People’s Republic of China, Email lcxin618@163.com
Background: The detection of tumor markers for predicting the therapeutic efficacy is relatively rare at present. The combined elevation of carcinoembryonic antigen (CEA), CA19-9, CA72-4, and CA125 and others may predict the efficacy of immunotherapy combined with chemotherapy, which is helpful for the precise screening of patients. This study aimed to investigate the correlation between serum tumor marker expression and clinical features, including stage, differentiation, primary site, and metastatic diameter. It also examined the relationship between tumor marker levels and the therapeutic efficacy in advanced gastric cancer patients.
Methods: We analyzed 327 patients with gastric or esophagogastric junction adenocarcinoma at Henan Provincial People’s Hospital. CEA, CA19-9, CA125, and CA72-4 levels were categorized as negative, single-marker elevated, or multiple-marker (≥ 2) elevated. Clinical features and survival outcomes were evaluated.
Results: Elevated marker numbers correlated significantly with advanced clinical stage, lower differentiation, Lauren classification type, and larger metastatic diameter. Patients with stage IV disease exhibited higher marker elevations than those with earlier stages. No significant association was observed between the number of tumor elevated markers and T/N stage, primary/metastatic site, or PD-L1 combined positive score > 5. After first-line chemotherapy, the objective response rate was positively correlated with elevated tumor marker numbers, single- rather than multiple-marker elevation showed better progression-free survival. In immunotherapy combined with chemotherapy, any increase in a tumor marker ≥ 5 times with a total metastasis diameter < 6 cm, indicating better short-term efficacy.
Conclusion: Elevated serum tumor markers are associated with higher tumor burden, advanced stage, and poorer differentiation in gastric cancer, potentially serving as disease severity and treatment response predictors.
Keywords: gastric cancer, serum tumor markers, immunochemotherapy, clinical features, treatment efficacy
1Department of Oncology, Henan University People’s Hospital, Zhengzhou, Henan, 450003, People’s Republic of China; 2Department of Oncology, Zhengzhou University People’s Hospital (Henan Provincial People’s Hospital), Zhengzhou, Henan, 450003, People’s Republic of China; 3Department of Medical Records Management, Henan Provincial People’s Hospital, Zhengzhou, Henan, 450003, People’s Republic of China; 4Department of Oncology, Henan Provincial People’s Hospital, Zhengzhou, Henan, 450003, People’s Republic of China; 5School of Public Health, Zhengzhou University, Zhengzhou, Henan, 450001, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Chuangxin Lu, Department of Oncology, Zhengzhou University People’s Hospital (Henan Provincial People’s Hospital), Zhengzhou, Henan, 450003, People’s Republic of China, Email lcxin618@163.com
Background: The detection of tumor markers for predicting the therapeutic efficacy is relatively rare at present. The combined elevation of carcinoembryonic antigen (CEA), CA19-9, CA72-4, and CA125 and others may predict the efficacy of immunotherapy combined with chemotherapy, which is helpful for the precise screening of patients. This study aimed to investigate the correlation between serum tumor marker expression and clinical features, including stage, differentiation, primary site, and metastatic diameter. It also examined the relationship between tumor marker levels and the therapeutic efficacy in advanced gastric cancer patients.
Methods: We analyzed 327 patients with gastric or esophagogastric junction adenocarcinoma at Henan Provincial People’s Hospital. CEA, CA19-9, CA125, and CA72-4 levels were categorized as negative, single-marker elevated, or multiple-marker (≥ 2) elevated. Clinical features and survival outcomes were evaluated.
Results: Elevated marker numbers correlated significantly with advanced clinical stage, lower differentiation, Lauren classification type, and larger metastatic diameter. Patients with stage IV disease exhibited higher marker elevations than those with earlier stages. No significant association was observed between the number of tumor elevated markers and T/N stage, primary/metastatic site, or PD-L1 combined positive score > 5. After first-line chemotherapy, the objective response rate was positively correlated with elevated tumor marker numbers, single- rather than multiple-marker elevation showed better progression-free survival. In immunotherapy combined with chemotherapy, any increase in a tumor marker ≥ 5 times with a total metastasis diameter < 6 cm, indicating better short-term efficacy.
Conclusion: Elevated serum tumor markers are associated with higher tumor burden, advanced stage, and poorer differentiation in gastric cancer, potentially serving as disease severity and treatment response predictors.
Keywords: gastric cancer, serum tumor markers, immunochemotherapy, clinical features, treatment efficacy